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Abstract
Background: Co-morbidity is a powerful predictor of health care outcomes and costs, as well as an
important cofounder in epidemiologic studies. The effect of co-morbidities is generally related to mortality
or complications. This study evaluated the association between co-morbidity and health-related quality of
life (HRQoL) in patients awaiting total joint replacement.
Methods: A total of 893 patients were recruited to the study between August 2002 and November 2003
in four Finnish hospitals. The effect of co-morbidity on HRQoL was measured by the generic 15D
instrument and by a Visual Analog Scale (VAS). Comparative variance analysis of socio-demographic and
clinical characteristics was described by using either an independent samples t-test or the Chi-square test.
The differences in each of the 15D dimensions and the overall 15D single index score for patients were
calculated. Two-sided p-values were calculated with the Levene Test for Equality of Variances.
Results: Patients with co-morbidity totaled 649; the incidence of co-morbidity was 73%. The mean
number of co-morbidities among the patients was two. At baseline the 15D score in patients with and
without co-morbidity was 0.778 vs 0.816, respectively. The difference of the score (0.038) was clinically
and statistically significant (P < 0.001). The patients' scores with and without co-morbidity on the different
15D dimensions related to osteoarthritis-moving, sleeping, usual activities, discomfort and symptoms,
vitality and sexual activity–were low in both groups. Patients with co-morbidity scored lower on the
dimensions of moving, vitality and sexual activity compared to the patients without co-morbidity. Co-
morbidity was significantly associated with a reduced HRQoL. Patients without co-morbidity had poorer
VAS, arthritis had strong effect to their quality of life compared to the patients with co-morbidity.
Conclusion: Assessing co-morbidity in patients placed on the waiting list for joint replacement may be
useful method to prioritization in medical decision-making for healthcare delivery. The assessment of co-
morbidities during waiting time is important as well as evaluating how the co-morbidity may affect the final
outcomes of the total joint replacement.
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Background
Chronic diseases have been shown to negatively affect
people's quality of life (QoL), and they are a common rea-
son for disability and early death. According to the Finn-
ish National Health 2000 Survey half of the Finnish
population aged over 30 has at least one chronic disease,
while 44 % of the working population and 82 % of senior
citizens have at least one chronic disease [1]. The decline
of the populations' self-reported sense of well-being is a
consequence of ageing, with no observable difference
between women and men. The commonest chronic dis-
eases in Finland are: cardiovascular disease, musculoskel-
etal disease, diabetes, and lung diseases [1].
Co-morbid or coexisting disease refers to the occurrence
of two or more diseases in the same individual. The pres-
ence of co-morbidity has a pervasive effect on QoL,
research, and clinical practice through its influence on
diagnosis, prognosis, treatment and, health care delivery.
Each co-morbid disease may have its own effect on QoL
while also having a clinical effect on patients' sense of
well-being. It is also important for studies of patients with
chronic disease in whom mortality is rare and the goal of
medical care is to control the course of the disease and
maximize the quality of life [2]. Evaluations on how dif-
ferent diseases affect patients' health-related quality of life
(HRQoL) focus mostly on the index disease, considering
the effect of co-morbidities to a lesser extent. However
when the focus is on the consequences–mortality, compli-
cations or in the costs of the medical care – co-morbidity
becomes an important denominator.
Co-morbidity can also play an important role in different
types of studies. Randomized controlled trials and prog-
nostic studies might be complicated by co-morbidity. It
can either act as a cofounder, threatening the internal
validity, or as an effect modifier, threatening the internal
and external validity of the study: therefore an efficient
method is needed to measure co-morbidity [3].
In Finland, total joint replacements (TJR) are surgical pro-
cedures with high volume and long waiting times. In
2003, primary hip and knee replacements were carried out
for almost 15500 patients [4]. For patients with primary
total joint replacement of hip the median waiting time
was 155 days, and for patients with primary total joint
replacement of knee, 205 days [4]. One reason for these
long waiting times is that OA is not itself life threatening.
However, some previous studies have reported that those
awaiting hip or knee replacement have a significantly
poorer quality of life and that arthritis becomes a chronic
and heavy burden to the patients [5,6]. Also few studies
having examined waiting time effects on health status in
OA patients have not been able to show that patients hav-
ing to wait longer would suffer from pain and functional
difficulties or poorer HRQoL than those with shorter wait-
ing [7,8].
In 2002, a prospective multi-centre study was started in
four Finnish hospitals. The aim of this larger study is to
assess the effect, the costs and the cost effectiveness of the
waiting time in patients awaiting TJR. This report is part of
this ongoing study. The objective of this paper is to evalu-
ate the effect of co-morbidity on HRQoL in OA patients
when placed on the waiting list for TJR.
Methods
Data collection
Between August 2002 and November 2003, a total of 893
OA patients were enrolled in the study in four Finnish
hospitals: the Helsinki University Central Hospital: Surgi-
cal Hospital, the Helsinki University Central Hospital:
Jorvi Hospital, the Coxa Hospital for Joint Replacement
and the Orton Orthopedic Hospital. Patients were
recruited into the study through contact with orthopedic
and practice staff.
The key inclusion criteria were a need for a primary TJR
due to OA of the hip or knee joint as evaluated by the hos-
pital surgeon; patient was aged 16 or older and placed on
the waiting list in a research hospital, and the patient was
willing and mentally able to participate in the study. The
key exclusion criteria were patients with rheumatoid
arthritis, congenital hemophilia or congenital deformi-
ties, and fractures. Patients completed a self-administered
questionnaire when placed on the waiting list for TJR. The
questionnaires were distributed to the patients at the hos-
pital and were returned by post. Common guidelines for
administering the questionnaires were provided at each
hospital. The patients completed a socio-demographic
form, reported their co-morbidities as diagnosed by a
medical doctor, completed the visual analog scale (VAS),
and also completed separate questionnaires for self-
reported sense of well-being and HRQoL. Each patient
provided informed consent. The study was approved by
the Helsinki University Central Hospital Surgery Ethics
Committee.
In this study, the co-morbidity data was collected from the
patients' reported co-morbidities as diagnosed by a medi-
cal doctor. The patients were assigned to subgroups
according to co-morbidity status. The patients' reported
diseases were classified according to the ICD10 [9], giving
nine diagnoses groups in total: tumors, diabetes mellitus,
respiratory disease, cardiovascular disease, high choles-
terol, mental health problems, muskuloskeletal system
diseases, endocrinological problems, and visual or hear-
ing problems.Health and Quality of Life Outcomes 2007, 5:16 http://www.hqlo.com/content/5/1/16
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Co-morbidity and Quality of Life
It is difficult to choose the most appropriate co-morbidity
measurement because comparative data on how the avail-
able instruments perform in different disease settings are
limited [10,11]. There are several reports about different
measurements and measurement combinations for
assessing co-morbidity. Instruments used in clinical
research to calculate co-morbidity include, for example,
the Carlson Index [13], the Cumulative Illness Rating
Scale (CIRS) [14], the Index of Coexistent Diseases
(ICED) [15] and the Kaplan Index [16]. Both generic and
disease-specific QoL instruments are used to assess the
effect of co-morbidities in clinical trials [12,17].
In this study the effect of co-morbidity was assessed as the
difference in HRQoL between the patients with and those
without co-morbidity. HRQoL was measured by using the
generic, multidimensional, standardized, and self-admin-
istered 15D instrument. The 15D is a Multi-Attribute-Util-
ity-Scale (MAU) measurement instrument [18] that
measures quality of life in 15 dimensions: moving, vision,
hearing, breathing, sleeping, eating, speech, eliminating,
vitality, mental functions, discomfort and symptoms,
depression, distress, energy and sexual activity. Each
dimension has a single question with 5 possible answer
options. The 15D can be used as a profile measure or to
give a single index score by means of population-based
preference weights. The index score is between 0 (being
dead) and 1 (being totally healthy). Completing the 15D
questionnaire takes 5–10 minutes and it describes the
respondents HRQoL at that point in time. The minimum
clinically important difference (MCID) in the 15D single
index score is interpreted as a difference of ± 0.03 or more,
which corresponds to the minimum difference that peo-
ple can generally distinguish [19]. The 15D favourably
compares with other quality of life instruments–such as
EuroQol (EQ-5D), Health Utility Index (HUI 1–3), Short
Form- 36 (SF-36), and the Nottingham Health Profile
(NHP)–in most of the important properties (e.g. respon-
siveness, reliability and validity) [20-22].
To evaluate the patients' sense of well-being, we used VAS,
which is a health-state rating scale. The measurement con-
sists of a line on a page with clearly defined endpoints.
The most preferred health state is placed at one end of the
line and the least preferred at the other end [23,24]. In this
study, VAS was a horizontal 100 mm long line (100 mm=
100%) illustrating the patients' health state deficiency at
that moment. It was used to evaluate the effect of arthritis
on health. Patients were asked to mark on the line which
part of the deficiency of health is due to arthritis. The
higher the number was–on scale from 0 to 100–the more
powerful was the effect of arthritis. In addition, the
patients' self-reported state of health was described with a
five-point scale, representing health states from excellent
to worst.
Statistical analysis
At the baseline (when placed on the waiting list) descrip-
tive statistics were used to describe the socio-demographic
and clinical characteristics of the patients. Comparative
variance analyses of socio-demographic and clinical char-
acteristics were described by using either an independent
samples t-test or the Chi-square test depending on
whether it was a continuous or nominal scale. The differ-
ences in each of the 15D dimensions and the overall 15D
single index score for patients were calculated. Two-sided
p-values were calculated with the Levene Test for Equality
of Variances, with the minimum significance level set at
5% (P-value < 0.05). The mean differences between each
of the dimensions were also calculated. Missing values for
the 15D were predicted by means of a regression model
with the patient's responses for other dimensions, and
also with data from the patients, with age and gender as
explanatory variables [22]. The missing values were esti-
mated if a minimum of 80% of dimensions had been
completed. Furthermore, the incidences of co-morbid
diagnoses and also the mean 15D score were calculated
for each diagnosis group in the model. Data analyses were
performed using SPSS version 12.0.1 for Windows.
Results
Of the 914 eligible patients recruited into this study,
twenty one were excluded because they didn't return the
questionnaire, leaving 893 patients in the study group.
The mean age of patients waiting for TJR was 66 years
(range 24–88) and 63% of the participants were female.
Patients with co-morbidity totaled 649, while patients
without co-morbidity totaled 244. The mean age in the
patients with co-morbidity was 67 years (range 25–87),
versus 64 years (range 24–88) without co-morbidity (P <
0.001). Patient's demographics are reported in Table 1.
The incidence of co-morbidity as a secondary or tertiary
illness was 73%. The mean number of co-morbidities
among the patients was two, and 363 (56% of co-morbid
patients) had three or more diagnosis. The BMI was high
in both groups (>25 which is the limit of overweight and
>30 is a limit of obese) but in the co-morbid group, the
BMI was higher than in the patients without co-morbidity
(P < 0.001). The patients' health state based on the five-
point scale was worse in the co-morbidity group. However
in the patients with co-morbidity, the effect of the OA in
the health-state deficiency as measured by VAS was 62%
versus 76% (P < 0.001) in the patients without co-mor-
bidity (Table 1).
The most common secondary diagnosis was cardiovascu-
lar disease (n = 419, 63%), followed by high cholesterol
(n = 225, 33%), diabetes mellitus (n = 225, 33%) andHealth and Quality of Life Outcomes 2007, 5:16 http://www.hqlo.com/content/5/1/16
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endocrinological problems (n = 225, 33%). The worst
15D score of 0.637 was for a patient with mental prob-
lems (Table 2).
At baseline the 15D score in patients with and without co-
morbidity was 0.778 vs 0.816, respectively. The difference
of the score (0.038) was clinically and statistically signifi-
cant (P < 0.001). The patients' scores with and without co-
morbidity on the different 15D dimensions related to
OA–moving, sleeping, usual activities, discomfort and
symptoms, vitality and sexual activity–were low in both
groups. Patients with co-morbidity scored lower on the
dimensions of moving, vitality and sexual activity com-
pared to the patients without co-morbidity, while patients
without co-morbidity scored lower in the dimensions of
seeing, hearing, breathing and elimination. The deteriora-
tion of HRQoL was significantly associated with co-mor-
bidity (Table 3).
Discussion
The aim of this study was to assess the effect of co-morbid-
ities on HRQoL at baseline in patients awaiting major
joint replacement in four Finnish hospitals. The main
finding of this study was that the HRQoL of all TJR
patients was poor but significantly worse in the patients
with co-morbidity. A secondary finding was that the VAS
health-rating instrument appears more appropriate as a
disease-specific instrument, as in this study, patients did
not necessarily assign the primary disease (arthritis in
most cases) as being the most prominent in affecting their
well-being. Furthermore, the five-point self-rated health
scale showed that the health state of patients with co-mor-
bidity was worse than the patients without co-morbidity,
Table 2: The co-morbidities among osteoarthritis patients and the mean 15D score in each diagnose groups, when placed on the 
waiting list for TJR
Co-morbidity Patients, n (%) 15D (± SD)
Cardiovascular disease 419 (63%) 0.775 (± 0.09)
High cholesterol 225 (34%) 0.769 (± 0.09)
Diabetes mellitus 225 (34%) 0.769 (± 0.09)
Endocrinological problems 225 (34%) 0.769 (± 0.09)
Other muskuloskeletal diseases 117 (18%) 0.758 (± 0.09)
Respiratory diseases 91 (14%) 0.758 (± 0.09)
Visual or hearing problems 54 (8%) 0.780 (± 0.07)
Tumors 25 (4%) 0.735 (± 0.08)
Mental problems 14 (2%) 0,637 (± 0.09)
Table 1: Demographic and clinical characteristics of TJR patients with and without co-morbidity when placed on the waiting list. 
Independent Sample T-test or Chi-square test
Characteristics Patients with co-morbidity Patients without co-morbidity P-value
(n = 649–6621) (n = 242–2441)
Age, years (mean ± SD) 67 ± 10 64 ± 11 0.000***
Females [n, (%)] 422(63) 132 (54) 0.008**
Marital status [n, (%)]
Married 411 (62) 160 (65) 0.155
Housing [n,%]
Living alone 227 (34) 62 (25) 0.008**
Basic education [n,%]
Low level 544 (82) 190(78) 0.130
Professional examination [n,%]
Low level 486 (75) 175 (73) 0.279
Employment status {n, (%)]
Retired 546 (82) 172(71) 0.000***
Health status [n, (%)]
Fair or poor 497 (75) 133 (55) 0.000***
VAS2 (mean ± SD) 62 ± 26 76 ± 24 0.000***
BMI3 (mean ± SD) 28.8 ± 4 27.2 ± 4 0.000***
1Number of observation varies due to missing values; 2VAS, visual analog scale (100 the worst, 0 the best value); 3BMI, body mass index (wt/ht2); ** 
P < 0.01, ***P < 0.001Health and Quality of Life Outcomes 2007, 5:16 http://www.hqlo.com/content/5/1/16
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which is in line with our results of a decline from the base-
line of HRQoL as measured by 15D.
Few studies have assessed the effect of co-morbidities on
the quality of life (QoL) by either a generic or a disease-
specific instrument. In 1999 Xuan et al. [2] reported how
different measuring methods differ when evaluating the
different effects of co-morbidities related to QoL. They
found that co-morbidity extensively affects generic QoL,
whereas the effect is considerably smaller for disease-spe-
cific measures. Salaffi et al. [17] studied the relationship
between OA, co-morbidity and HRQoL in older adults
compared with matched healthy controls. They found
that 55% of patients reporting at least one chronic coexist-
ing disease and OA of the lower extremities suffer a signif-
icant impact on multiple dimensions of HRQoL
compared with healthy controls. The most significant
impacts were seen in physical functions, physical roles,
and pain. Both of these findings are in line with our
results.
Cardiovascular disease is the most common disease in
Finland [1] and in our study, it was also the most com-
mon coexisting disease. According to Shan et al. [14] if OA
is related in some way to a co-morbidity i.e. cardiovascu-
lar disease, it might negatively affect the outcomes of the
joint replacement. Furthermore, several studies have testi-
fied that arthritis is considered to be a risk factor for other
co-morbidity conditions such as hypertension, heart dis-
ease, diabetes and chronic lung disease [17,25].
Limitations of this study include the severity of the co-
morbidity not being known, and the fact that arthritis was
necessarily classified as the primary disease. However, we
can assume that the patients' coexisting diseases were not
life threatening, because the severity of the co-morbidity
in the patients is usually an exclusion criterion for the sur-
gical operation. The other limitation related to co-mor-
bidity data was that the data was collected from the
patients, not from the patient's medical records. However
the patients were asked to name only those co-morbidities
diagnosed by a medical doctor.
Co-morbidity has been commonly measured as an index
in studies where medical records have been used to inves-
tigate mortality, complications or the costs of the medical
care. A significantly strong association between co-mor-
bidity and mortality, complications and increasing in hos-
pital costs [2,12,14,25-28] has been shown, but to our
knowledge there are no previous studies on the effect of
co-morbidity on the HRQoL in the patients waiting for
TJR.
Our findings show statistically significant differences in
the 15D-index between the groups with and without co-
morbidity. This suggests that a generic measurement
instrument is sensitive enough to identify the effects of co-
morbidities. This study provides evidence of co-morbidity
being a factor that significantly affects HRQoL, and which
can be assessed when the patients are placed on the wait-
ing list. Moreover, some studies have suggested that the
use of a generic HRQoL measurement in the studies of OA
Table 3: 15D dimensions and score at baseline in total joint replacement patients withand without co-morbidity. Levene's Test for 
Equality of Variances
Dimensions Patients co-morbidity (n = 662) Patients no co-morbidity (n = 242)
Mean SE Mean SE Mean difference P-value
Moving 0.590 0.137 0.626 0.137 0.036 0.000***
Seeing 0.905 0.181 0.934 0.152 0.030 0.015*
Hearing 0.915 0.154 0.945 0.129 0.031 0.003**
Breathing 0.812 0.235 0.937 0.138 0.125 0.000***
Sleeping 0.723 0.217 0.738 0.210 0.014 0.375
Eating 0.991 0.057 0.997 0.032 0.006 0.051
Communication 0.986 0.070 0.993 0.046 0.007 0.102
Elimination 0.827 0.216 0.910 0.162 0.083 0.000***
Usual activities 0.643 0.222 0.679 0.239 0.036 0.045*
Mental 0.889 0.176 0.906 0.162 0.017 0.180
Discomfort and 
symptoms
0.506 0.236 0.540 0.240 0.033 0.065
Depression 0.837 0.171 0.854 0.167 0.016 0.196
Distres 0.848 0.177 0.865 0.162 0.017 0.168
Vitality 0.737 0.179 0.789 0.153 0.052 0.000***
Sexual activity 0.732 0.281 0.783 0.243 0.051 0.008**
15D-index 0.778 0.092 0.816 0.281 0.038 0.000***
*P < 0.05; **P < 0.01;***P < 0.001Health and Quality of Life Outcomes 2007, 5:16 http://www.hqlo.com/content/5/1/16
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where co-morbidity is common would be useful in char-
acterizing the global burden of this disease [16,17].
Conclusion
Severity of OA was the only inclusion criteria of patients
when placed on the waiting list, and the surgery was per-
formed according to the hospital's routine procedure, this
study had no effect to this. In these analyses, we found
that the HRQoL of all TJR patients was poor but signifi-
cantly worse in the patients with co-morbidity. Further,
VAS health-rating instrument appears more appropriate
as a disease-specific instrument, as being the most promi-
nent in affecting patients' well-being, and also the five-
point self-rated health scale showed that the health state
of patients with co-morbidity was worse than the patients
without co-morbidity. Assessing the co-morbidity condi-
tion at baseline might operate as an instrument to help in
prioritization in medical decision-making for healthcare
delivery. The assessment of co-morbidities during waiting
time is important as well as evaluating how the co-mor-
bidity may affect the final outcomes of the whole proce-
dure.
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